UNSPSC 51203603: Napirimus

This classification denotes an immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 45081SG6XT. European Medicines Agency schedules Napirimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09156MIG. Napirimus generally arises in the molecular formula C17H13NO3.

UNSPSC 51203603 Napirimus is a Commodity code under which state and local governments procure naloxone, drug deactivation systems, generic pharmaceuticals, over-the-counter medications, and medical and first aid supplies for public health, emergency response, and institutional healthcare programs. The code encompasses both standalone naloxone procurement for community health initiatives and broader pharmaceutical supply contracts serving multiple state and local facilities through cooperative purchasing arrangements and direct vendor relationships with authorized wholesalers.

State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances. Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Department of Administration (administering the Minnesota Multistate Cooperative Purchasing Alliance) have posted recent opportunities. Recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB 60459723LAS, due July 26, 2023); the City of Tampa's sheltered-market IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000.00 and a 5 percent bid discount for certified Small Local Business Enterprises (due March 13, 2026); the Texas HHS Commission's Request for Information on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (RFI HHS0017013, due April 3, 2026); and the Minnesota Department of Administration's RFP for generic multi-source pharmaceuticals and OTC products through MMCAP, serving participating state and local government facilities including Oregon (RFP S1070000015802, due March 26, 2026). Geographic activity centers on Florida, Texas, and Minnesota, with multistate reach through the MMCAP cooperative purchasing vehicle.